ClinicalTrials.Veeva

Menu

Bioequivalency Study of Exemestane 25 mg Tablet Under Fed Conditions

Roxane Laboratories logo

Roxane Laboratories

Status

Completed

Conditions

Breast Cancer

Treatments

Drug: exemestane

Study type

Interventional

Funder types

Industry

Identifiers

NCT01331434
EXEM-02

Details and patient eligibility

About

The objective of this study was to prove the bioequivalence of Exemestane 25 mg tablet under fed conditions.

Enrollment

47 patients

Sex

Female

Ages

18 to 55 years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

  • No clinically significant abnormal findings on the physical examination, medical history, or clinical laboratory results during screening

Exclusion criteria

  • Positive test for HIV, Hepatitis B, or Hepatitis C.
  • Treatment with known enzyme altering drugs.
  • History of allergic or adverse response to exemestane or any comparable or similar product.

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Crossover Assignment

Masking

None (Open label)

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems